All News

BioOutsource, a contract testing services provider to the biopharmaceutical industry, has opened a new facility in Cambridge, Massachusetts. The facility marks the company's first North American offices, which were opened in response to increasing demand for the company's bioanalytical and biosafety services, particularly in the field of biologic and biosimilar characterisation.

FDA issues draft guidance to minimize medication errors.

AstraZeneca and BIND Therapeutics have formed a strategic collaboration to develop and commercialise BIND's Accurin, a targeted and programmable cancer nanomedicine, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

Third compounding pharmacy recalls products due to FDA inspection.

Unique technology expands Entegris? fluid-sensing and control offering.

FDA has released Guidance for Industry: Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination.

New manufacturing route improves availability of ingredient for malaria treatment.

Big Biotech companies are demonstrating they are better positioned than their pharmaceutical industry counterparts to meet changing demands.

The facility in Hangzhou will package Merck medicines for China and the Asia-Pacific region.

Amgen Inc. has agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act.

$13.6 billion deal strengthens Thermo?s leading role.

FDA inspections of compounding pharmacies manufacturing sterile-drug products lead to voluntary recalls.

New facility for Bio-Manguinhos will use plant-based protein expression technology.

The process-driven system reduces total cost of ownership.

FDA's FY 2014 budget includes more than $10 million above the 2012 budget for inspections of products and ingredients manufactured in China.

The alliance will develop treatments based on Isis? antisense technology.

FDA inspections of compounding pharmacies result in FDA-483 citations.

Prefilled-syringe line features automation and novel disinfection techniques.

The company expands to add process-development and clinical-manufacturing capabilities at its large-scale bulk biologics facility.

Company is notified of GMP violations at facility in Catania, Italy.

Maryland is the latest state to consider whether to include additional requirements for substitution of biological products.

Catalent Pharma Solutions has acquired a license to market Redwood Bioscience 's proprietary SMARTag precision protein-chemical engineering technology.

Dr. Reddy's Laboratories has announced plans to relocate its North America headquarters and establish a R&D facility in Princeton, New Jersey.

Regeneron, a biopharmaceutical company based in New York, has announced plans to expand its corporate headquarters and laboratories in Westchester. This expansion will create more than 400 new highly skilled jobs and further cement Hudson Valley's reputation as an emerging epicenter for biopharmaceutical growth.

Company considers investment in insulin cartridge-filling and insulin API manufacturing capacity in the US.

Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars.

Company issues voluntary recall after learning of complaints of an uncharacteristic odor coming from Levoxyl bottles.

The Biotechnology Industry Organization (BIO) announced the companies confirmed to present at the 2013 BIO International Convention.

Ajinomoto Co. Inc. reported the completion of a previously announced acquisition of Althea Technologies.

Novartis loses an appeal in seeking patent protection in India for its anticancer drug.